Risk factors that are associated with adrenal insufficiency among patients with fever of unknown origin.

Postgraduate medicine Pub Date : 2023-09-01 Epub Date: 2023-10-24 DOI:10.1080/00325481.2023.2261355
Ji Won Ko, Seung Eun Lee, Jung Hwan Park, Bongyoung Kim
{"title":"Risk factors that are associated with adrenal insufficiency among patients with fever of unknown origin.","authors":"Ji Won Ko,&nbsp;Seung Eun Lee,&nbsp;Jung Hwan Park,&nbsp;Bongyoung Kim","doi":"10.1080/00325481.2023.2261355","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adrenal insufficiency is one of the causes of fever of unknown origin (FUO). The purpose of this study is to find out risk factors that are associated with adrenal insufficiency in FUO patients.</p><p><strong>Methods: </strong>This study was conducted retrospectively in a tertiary hospital with 846 beds in South Korea. All adult inpatients (age ≥19 years) who have requested a consult with the department of infectious disease for FUO between 1 July 20191 July 2019 and 30 June 202030 June 2020 were included in the study. Among them, those who underwent an adrenocorticotropic hormone (ACTH) stimulation test and had a fever of 37.8°C or higher within 48 hours of the ACTH stimulation test were finally included in the study subjects.</p><p><strong>Results: </strong>A total of 202 FUO patients were enrolled and 61 (30.1%) were finally diagnosed with adrenal insufficiency. In a multivariate analysis, use of immunosuppressant within 3 months (OR 6.06, 95% CI 1.82-20.13, <i>P</i> = 0.003), use of corticosteroid within 3 months (OR 8.23, 95% CI 1.35-50.17, <i>P</i> = 0.022), sodium ≥ 136.7 (OR 3.43, 95% CI 1.49-7.88, <i>P</i> = 0.004), and calcium ≥ 8.4 (OR 0.31, 95% CI 0.14-0.71, <i>P</i> = 0.005) were proven to be factors associated with adrenal insufficiency in FUO patients.</p><p><strong>Conclusion: </strong>In conclusion, 30.1% of FUO patients were diagnosed with adrenal insufficiency. The risk factors that are associated with adrenal insufficiency in FUO patients were immunosuppressive prescription or systemic steroid prescription within 3 months, or with sodium ≥ 136.7 or calcium < 8.4.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postgraduate medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/00325481.2023.2261355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Adrenal insufficiency is one of the causes of fever of unknown origin (FUO). The purpose of this study is to find out risk factors that are associated with adrenal insufficiency in FUO patients.

Methods: This study was conducted retrospectively in a tertiary hospital with 846 beds in South Korea. All adult inpatients (age ≥19 years) who have requested a consult with the department of infectious disease for FUO between 1 July 20191 July 2019 and 30 June 202030 June 2020 were included in the study. Among them, those who underwent an adrenocorticotropic hormone (ACTH) stimulation test and had a fever of 37.8°C or higher within 48 hours of the ACTH stimulation test were finally included in the study subjects.

Results: A total of 202 FUO patients were enrolled and 61 (30.1%) were finally diagnosed with adrenal insufficiency. In a multivariate analysis, use of immunosuppressant within 3 months (OR 6.06, 95% CI 1.82-20.13, P = 0.003), use of corticosteroid within 3 months (OR 8.23, 95% CI 1.35-50.17, P = 0.022), sodium ≥ 136.7 (OR 3.43, 95% CI 1.49-7.88, P = 0.004), and calcium ≥ 8.4 (OR 0.31, 95% CI 0.14-0.71, P = 0.005) were proven to be factors associated with adrenal insufficiency in FUO patients.

Conclusion: In conclusion, 30.1% of FUO patients were diagnosed with adrenal insufficiency. The risk factors that are associated with adrenal insufficiency in FUO patients were immunosuppressive prescription or systemic steroid prescription within 3 months, or with sodium ≥ 136.7 or calcium < 8.4.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
不明原因发热患者中与肾上腺功能不全相关的危险因素。
背景:肾上腺功能不全是不明原因发热(FUO)的原因之一。本研究的目的是找出与FUO患者肾上腺功能不全相关的危险因素。方法:本研究在韩国一家拥有846张床位的三级医院进行回顾性研究。所有成年住院患者(年龄≥19岁 年),他们在2019年7月1日至2019年7月份91日至2020年6月30日期间要求向FUO传染病科咨询。其中,接受促肾上腺皮质激素(ACTH)刺激测试并在48小时内发烧37.8°C或更高的患者 ACTH刺激试验的小时数最终被纳入研究对象。结果:共有202名FUO患者入选,61名(30.1%)最终被诊断为肾上腺功能不全。在多变量分析中,免疫抑制剂在3 月(OR 6.06,95%CI 1.82-20.13,P = 0.003),3年内使用皮质类固醇 月(OR 8.23,95%CI 1.35-50.17,P = 0.022),钠 ≥ 136.7(或3.43,95%置信区间1.49-7.88,P = 0.004)和钙 ≥ 8.4(或0.31,95%CI 0.14-0.71,P = 0.005)被证明是FUO患者肾上腺功能不全的相关因素。结论:总的来说,30.1%的FUO患者被诊断为肾上腺功能不全。FUO患者中与肾上腺功能不全相关的危险因素是3年内的免疫抑制处方或全身类固醇处方 月,或用钠 ≥ 136.7或钙
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The triglyceride-glucose index as an indicator of latent atherogenicity of the plasma lipid profile in healthy men with normolipidaemia. Pentoxifylline improves anemia through its novel effect on hypoxia-inducible factor-2 alpha in hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial. The masters athlete and use of antihypertensive medications. Evaluating cardiac electrophysiological markers for predicting arrhythmic risk in hypothyroid patients. SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1